Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin

Telisotuzumab vedotin is a MET-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with EGFR wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chien-Yu, Wei, Sheng-Huan, Chen, Yi-Lin, Lee, Chung-Ta, Wu, Shang-Yin, Ho, Chung-Liang, Pavlick, Dean C., Su, Po-Lan, Lin, Chien-Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404301/
https://www.ncbi.nlm.nih.gov/pubmed/36033470
http://dx.doi.org/10.3389/fonc.2022.919123
_version_ 1784773607699775488
author Lin, Chien-Yu
Wei, Sheng-Huan
Chen, Yi-Lin
Lee, Chung-Ta
Wu, Shang-Yin
Ho, Chung-Liang
Pavlick, Dean C.
Su, Po-Lan
Lin, Chien-Chung
author_facet Lin, Chien-Yu
Wei, Sheng-Huan
Chen, Yi-Lin
Lee, Chung-Ta
Wu, Shang-Yin
Ho, Chung-Liang
Pavlick, Dean C.
Su, Po-Lan
Lin, Chien-Chung
author_sort Lin, Chien-Yu
collection PubMed
description Telisotuzumab vedotin is a MET-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with EGFR wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent therapy has not been standardized. Here, we present a case of a 56-year-old woman diagnosed with KIF5B-MET fusion-positive non-small cell lung cancer who had a durable response to capmatinib after acquired resistance to telisotuzumab vedotin.
format Online
Article
Text
id pubmed-9404301
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94043012022-08-26 Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin Lin, Chien-Yu Wei, Sheng-Huan Chen, Yi-Lin Lee, Chung-Ta Wu, Shang-Yin Ho, Chung-Liang Pavlick, Dean C. Su, Po-Lan Lin, Chien-Chung Front Oncol Oncology Telisotuzumab vedotin is a MET-targeting antibody–drug conjugate that has demonstrated a good treatment response in patients with EGFR wild-type MET-overexpressing non-squamous non-small cell lung cancer. However, patients have been reported to acquire resistance to this drug, and the subsequent therapy has not been standardized. Here, we present a case of a 56-year-old woman diagnosed with KIF5B-MET fusion-positive non-small cell lung cancer who had a durable response to capmatinib after acquired resistance to telisotuzumab vedotin. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9404301/ /pubmed/36033470 http://dx.doi.org/10.3389/fonc.2022.919123 Text en Copyright © 2022 Lin, Wei, Chen, Lee, Wu, Ho, Pavlick, Su and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lin, Chien-Yu
Wei, Sheng-Huan
Chen, Yi-Lin
Lee, Chung-Ta
Wu, Shang-Yin
Ho, Chung-Liang
Pavlick, Dean C.
Su, Po-Lan
Lin, Chien-Chung
Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
title Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
title_full Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
title_fullStr Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
title_full_unstemmed Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
title_short Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
title_sort case report: salvage capmatinib therapy in kif5b-met fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404301/
https://www.ncbi.nlm.nih.gov/pubmed/36033470
http://dx.doi.org/10.3389/fonc.2022.919123
work_keys_str_mv AT linchienyu casereportsalvagecapmatinibtherapyinkif5bmetfusionpositivelungadenocarcinomawithresistancetotelisotuzumabvedotin
AT weishenghuan casereportsalvagecapmatinibtherapyinkif5bmetfusionpositivelungadenocarcinomawithresistancetotelisotuzumabvedotin
AT chenyilin casereportsalvagecapmatinibtherapyinkif5bmetfusionpositivelungadenocarcinomawithresistancetotelisotuzumabvedotin
AT leechungta casereportsalvagecapmatinibtherapyinkif5bmetfusionpositivelungadenocarcinomawithresistancetotelisotuzumabvedotin
AT wushangyin casereportsalvagecapmatinibtherapyinkif5bmetfusionpositivelungadenocarcinomawithresistancetotelisotuzumabvedotin
AT hochungliang casereportsalvagecapmatinibtherapyinkif5bmetfusionpositivelungadenocarcinomawithresistancetotelisotuzumabvedotin
AT pavlickdeanc casereportsalvagecapmatinibtherapyinkif5bmetfusionpositivelungadenocarcinomawithresistancetotelisotuzumabvedotin
AT supolan casereportsalvagecapmatinibtherapyinkif5bmetfusionpositivelungadenocarcinomawithresistancetotelisotuzumabvedotin
AT linchienchung casereportsalvagecapmatinibtherapyinkif5bmetfusionpositivelungadenocarcinomawithresistancetotelisotuzumabvedotin

Ejemplares similares